Keyphrases
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Nave
100%
Prednisone
70%
Abiraterone Acetate
70%
Docetaxel
60%
Androgen Deprivation Therapy
60%
Newly Diagnosed
30%
Overall Survival
30%
Low Risk
20%
Combined Therapy
20%
Visceral Metastases
20%
High-risk Features
20%
Abiraterone
20%
Side Effect Profile
10%
Bone Lesions
10%
Axial Skeleton
10%
High Risk
10%
Bone Metastasis
10%
Survival Improvement
10%
Combined Treatment
10%
Patient Preference
10%
Drug Side Effects
10%
Gleason Score
10%
Low Volume
10%
Narrative Summary
10%
Risk Stratification
10%
PubMed Search
10%
Disease Progression
10%
Overall Survival Benefit
10%
Medicine and Dentistry
Prednisone
100%
Abiraterone Acetate
100%
Prostate Cancer
100%
Docetaxel
85%
Androgen Deprivation Therapy
85%
Overall Survival
57%
Abiraterone
28%
Combined Therapy
28%
Visceral Metastasis
28%
Bone Lesion
14%
Health Care Cost
14%
Patient Preference
14%
Adverse Drug Reaction
14%
Risk Stratification
14%
Disease Exacerbation
14%
Axial Skeleton
14%
Post-Hoc Analysis
14%
Gleason Score
14%
Bone Metastasis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Prednisone
100%
Prostate Cancer
100%
Abiraterone Acetate
100%
Docetaxel
85%
Androgen
85%
Overall Survival
57%
Visceral Metastasis
28%
Abiraterone
28%
Adverse Drug Reaction
14%
Bone Metastasis
14%
Gleason Score
14%
Bone Lesion
14%
Disease Exacerbation
14%